Federal Hemp Definition: Legal Standards, THC Limits & Industry Impact

Executive Summary

The federal definition of hemp—Cannabis sativa L. with no more than 0.3% delta-9 THC on a dry weight basis—stands at the center of a multibillion-dollar industry and a regulatory crisis that affects farmers, processors, retailers, and state regulators across all 50 states. Established by the 2018 Farm Bill (Agricultural Improvement Act of 2018, Public Law 115-334), this single threshold determines whether a cannabis plant is legal hemp or federally controlled marijuana. As of August 2026, proposed changes to this definition by the U.S. Department of Agriculture and the Drug Enforcement Administration have created uncertainty for an industry that generated $28.4 billion in retail sales in 2025, according to Hemp Industry Daily. Vermont hemp businesses, along with operators in Colorado, Kentucky, Oregon, and North Carolina, face potential product recalls, crop destruction, and criminal liability if federal agencies adopt stricter measurement protocols or expand the definition to include total THC rather than delta-9 THC alone.

The stakes extend beyond commerce. The hemp definition affects medical research access, state-legal CBD markets, industrial fiber production, and the legal status of hemp-derived cannabinoids including delta-8 THC, THCA, and HHC. Farmers who planted crops under one regulatory framework may harvest them under another. Retailers selling compliant products today could face DEA enforcement tomorrow. This topic hub provides the complete legal, historical, and market context operators and policymakers need to navigate the evolving federal hemp landscape.

Why This Matters

The 0.3% THC threshold affects more than 16,000 licensed hemp farmers, 3,200 processors, and an estimated 35,000 retail locations nationwide, with direct implications for consumer access to CBD products, industrial hemp materials, and state-legal cannabis markets. According to USDA's 2025 National Hemp Report, licensed hemp cultivation spanned 54,300 acres across 47 states and three territories, with total farm-gate value exceeding $824 million. Kentucky alone licensed 1,840 growers cultivating 8,200 acres; Colorado reported 1,450 licenses covering 6,700 acres; and Oregon documented 980 licenses on 5,100 acres.

For consumers, the definition determines which products remain legal. The CBD market—valued at $6.4 billion in 2025 by the Brightfield Group—relies entirely on the hemp definition. Products containing CBD, CBG, CBN, and other non-intoxicating cannabinoids derived from compliant hemp remain legal under federal law and accessible without a prescription. A redefinition that includes total THC or THCA could immediately render thousands of products non-compliant, forcing recalls and creating supply shortages.

State regulators face operational chaos. Thirty-nine states operate USDA-approved hemp programs under 7 U.S.C. § 1639p, which requires state plans to align with federal definitions. Changes to the federal standard trigger mandatory state plan amendments, legislative sessions, and enforcement protocol revisions. States like Vermont, which built regulatory infrastructure around the 2018 definition, must choose between maintaining state-legal markets that conflict with federal law or shutting down compliant businesses overnight.

Financial institutions and payment processors watch closely. Banks providing services to hemp businesses under the 2018 Farm Bill's safe harbor provisions could face renewed Bank Secrecy Act compliance burdens if the definition changes. Credit card networks including Visa and Mastercard have issued guidance permitting hemp CBD transactions based on the current definition; a shift could force payment processing shutdowns affecting billions in annual transaction volume.

Background and History: From Prohibition to the 0.3% Standard

The 0.3% delta-9 THC threshold originated not from pharmacological research but from a 1976 taxonomic study by Canadian plant scientists Ernest Small and Arthur Cronquist, who proposed the figure as an arbitrary dividing line to distinguish fiber-type cannabis cultivars from drug-type varieties. Their study, published in the journal Taxon, acknowledged the threshold had "no practical significance" for intoxication potential but provided a measurable standard for botanical classification. This academic distinction would become federal law 42 years later.

The Controlled Substances Act Era (1970-2014)

The Controlled Substances Act of 1970 (21 U.S.C. § 812) placed marijuana in Schedule I, defining it as "all parts of the plant Cannabis sativa L." with narrow exceptions for mature stalks, sterilized seeds, and fiber. This definition made no distinction based on THC content, effectively prohibiting all cannabis cultivation regardless of intoxication potential. Hemp farming, common in the United States through World War II, became a federal crime. The DEA interpreted the CSA to prohibit even low-THC industrial hemp, rejecting state licensing programs in Hawaii and North Dakota during the 1990s and early 2000s.

Kentucky led early reform efforts. In 2013, the Kentucky Department of Agriculture under Commissioner James Comer began advocating for industrial hemp legalization, citing the state's historical role as the nation's largest hemp producer in the 19th century. North Dakota farmer Wayne Hauge challenged the DEA's hemp seed import restrictions in federal court, though the Eighth Circuit upheld the prohibition in Hauge v. DEA (2002).

The 2014 Farm Bill Pilot Programs

The Agricultural Act of 2014 (Public Law 113-79, Section 7606) created the first federal hemp exception since 1970. The provision, championed by Senate Majority Leader Mitch McConnell of Kentucky and Senator Ron Wyden of Oregon, authorized state agriculture departments and higher education institutions to operate hemp pilot programs for research purposes. The statute defined industrial hemp as Cannabis sativa L. with "a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."

This marked the first appearance of the 0.3% standard in federal law. Between 2014 and 2018, 41 states enacted hemp pilot programs under Section 7606 authority. Kentucky issued 1,047 pilot licenses by 2018; Colorado licensed 730 growers; and Oregon documented 589 participants. The pilot programs generated $1.1 billion in total economic activity according to Vote Hemp's 2018 U.S. Hemp Crop Report, but legal ambiguity persisted. The DEA maintained that hemp-derived CBD remained a Schedule I controlled substance, creating conflicts with state programs and payment processors.

The 2018 Farm Bill: Full Legalization

The Agriculture Improvement Act of 2018, signed December 20, 2018, removed hemp from Schedule I entirely. Section 10113 amended the Controlled Substances Act to exclude "hemp" from the definition of marijuana, defining hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."

The statute assigned regulatory authority to USDA for cultivation (7 U.S.C. § 1639p) and to FDA for food, drug, and cosmetic applications (21 U.S.C. § 301 et seq.). States could prohibit hemp production within their borders, but compliant hemp and hemp-derived products became legal to transport in interstate commerce. Senator McConnell, who secured the provision as a condition of his support for the broader farm bill, called it "a victory for American farmers and American consumers."

USDA's Interim Final Rule (2019) and Final Rule (2021)

USDA published its Interim Final Rule on October 31, 2019 (84 Fed. Reg. 58522), establishing the U.S. Domestic Hemp Production Program. The rule required testing of hemp crops within 15 days of anticipated harvest using DEA-registered laboratories, with samples analyzed for total THC—the sum of delta-9 THC and THCA multiplied by 0.877 to account for decarboxylation. This created immediate controversy. While the statutory definition referenced only delta-9 THC, USDA's testing protocol effectively imposed a lower threshold by including THCA, the non-intoxicating acid precursor that converts to delta-9 THC when heated.

Industry groups including the U.S. Hemp Roundtable and the Hemp Industries Association submitted more than 4,600 comments opposing the total THC standard. Farmers reported crop failure rates exceeding 20% in states including Oregon, Colorado, and Montana, where compliant plants tested "hot" (above 0.3% total THC) due to THCA content. USDA received petitions to raise the threshold to 1% total THC or revert to delta-9 THC measurement only.

The Final Rule, published January 19, 2021 (86 Fed. Reg. 5596), retained the total THC testing protocol but extended the harvest window to 30 days and raised the negligence threshold from 0.5% to 1.0% total THC. Crops testing between 0.3% and 1.0% could be remediated or destroyed without triggering a negligence report; those above 1.0% required reporting to USDA and potential license suspension. The rule took effect March 22, 2021, and remains in force as of August 2026.

The Delta-8 THC Controversy (2020-Present)

The 2018 Farm Bill's broad language—"all derivatives, extracts, cannabinoids"—created an unintended market for intoxicating hemp-derived cannabinoids. Delta-8 THC, a psychoactive isomer of delta-9 THC, occurs naturally in cannabis at trace levels but can be synthesized from CBD through chemical conversion. Manufacturers argued that delta-8 derived from compliant hemp met the statutory definition, as the finished product contained less than 0.3% delta-9 THC.

The DEA disagreed. In an August 2020 Interim Final Rule on hemp regulations (85 Fed. Reg. 51639), the agency stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," including delta-8 THC produced through chemical synthesis. The Hemp Industries Association challenged this interpretation, arguing the 2018 Farm Bill contained no synthetic cannabinoid exception. As of August 2026, the issue remains unresolved in federal court, with the Ninth Circuit considering the matter in Hemp Industries Association v. DEA (No. 23-1422).

Twenty-two states banned delta-8 THC sales between 2021 and 2025, including Colorado, New York, and Oregon. Fifteen states explicitly legalized and regulated it, including Michigan, Massachusetts, and Nevada. The remaining states operate in legal limbo, with retailers selling products of uncertain federal status.

THCA Flower and the "Loophole" Debate (2023-Present)

Beginning in 2023, hemp retailers began selling dried cannabis flower labeled as "THCA hemp"—products containing less than 0.3% delta-9 THC but high levels of THCA, which converts to intoxicating delta-9 THC when smoked or vaporized. These products, indistinguishable from marijuana flower in appearance and effect, technically complied with the statutory definition's delta-9 THC limit while circumventing the intent of the law.

The DEA issued guidance in May 2024 stating that THCA flower intended for smoking constitutes marijuana under the CSA, as the "intended use" involves decarboxylation. However, the agency has not pursued enforcement actions, creating a gray market estimated at $2.8 billion in 2025 sales according to Whitney Economics. Vermont, Tennessee, and Minnesota banned THCA flower sales in 2025; Texas and Florida moved to regulate it as adult-use cannabis; and North Carolina proposed emergency rules in July 2026.

Key Players in the Federal Hemp Definition Debate

U.S. Department of Agriculture

USDA's Agricultural Marketing Service administers the U.S. Domestic Hemp Production Program under 7 CFR Part 990. The agency reviews state and tribal hemp plans, licenses growers in states without approved programs, and sets testing standards. USDA has faced criticism from both sides: industry groups argue the total THC testing protocol is too strict, while law enforcement agencies contend the 30-day harvest window allows manipulation. In June 2026, USDA Administrator Bruce Summers told the House Agriculture Committee the agency was "reviewing the scientific basis" for the 0.3% threshold but offered no timeline for potential changes.

Drug Enforcement Administration

The DEA retains authority over controlled substances scheduling and enforcement. While the 2018 Farm Bill removed hemp from Schedule I, the DEA interprets its mandate to prevent diversion of intoxicating cannabinoids. The agency's 2020 synthetic cannabinoid rule and 2024 THCA guidance reflect ongoing tension between statutory hemp legalization and the CSA's prohibition on marijuana. DEA Administrator Anne Milgram stated in March 2026 that the agency was "concerned about products that exploit technical compliance while delivering marijuana-like intoxication."

Food and Drug Administration

FDA regulates hemp-derived CBD in food, beverages, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). The agency has declined to establish a regulatory framework for CBD despite industry petitions, citing safety concerns and the need for additional research. As of August 2026, FDA maintains that CBD cannot be added to food or sold as a dietary supplement because it was investigated as a drug (Epidiolex) before being marketed in foods. This position creates a paradox: hemp-derived CBD is federally legal under the Farm Bill but cannot be legally sold in most consumer products under FDA rules.

U.S. Hemp Roundtable

The industry's primary advocacy organization, led by General Counsel Jonathan Miller, represents more than 1,600 member companies including cultivators, processors, retailers, and ancillary service providers. The Roundtable has lobbied for FDA CBD regulation, opposed total THC testing standards, and supported federal legislation to clarify the legal status of hemp-derived cannabinoids. In July 2026, the organization submitted a white paper to USDA proposing a 1% total THC threshold and a 60-day harvest testing window.

National Association of State Departments of Agriculture

NASDA coordinates state agriculture agencies' hemp program implementation. The organization has advocated for regulatory flexibility, arguing that one-size-fits-all federal rules fail to account for regional growing conditions and crop genetics. NASDA's 2025 hemp policy resolution called for "science-based THC thresholds that reflect modern breeding capabilities and environmental variability."

Hemp Industries Association

Founded in 1994, HIA represents legacy hemp businesses focused on industrial fiber, grain, and seed oil. The organization has challenged DEA interpretations of the 2018 Farm Bill in federal court and advocated for clear distinctions between industrial hemp products and intoxicating cannabinoid markets. HIA President Rick Trojan said in a June 2026 statement that "conflating CBD with delta-8 and THCA undermines the legitimate hemp industry and invites federal crackdown."

Legal and Regulatory Framework

The federal hemp definition operates within a complex web of statutes, agency rules, and court decisions that create overlapping and sometimes contradictory requirements for growers, processors, and retailers.

Statutory Foundations

The Controlled Substances Act (21 U.S.C. § 802(16)) defines marijuana as "all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin" with exceptions for mature stalks, fiber, sterilized seeds, and—since 2018—hemp. The 2018 Farm Bill's amendment (7 U.S.C. § 1639o) defines hemp as Cannabis sativa L. with "a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."

This creates a binary classification: cannabis meeting the definition is hemp (legal); cannabis exceeding it is marijuana (Schedule I). No intermediate category exists. A plant measuring 0.29% delta-9 THC is hemp; at 0.31% it becomes a federally controlled substance subject to criminal penalties under 21 U.S.C. § 841.

USDA Hemp Regulations (7 CFR Part 990)

USDA's regulations require states and tribes to submit hemp production plans for approval. Approved plans must include procedures for maintaining information on land where hemp is produced, testing THC concentration, disposing of non-compliant plants, and licensing requirements. As of August 2026, 39 states and six tribes operate USDA-approved programs; USDA directly licenses growers in the remaining states.

Testing must occur within 30 days of anticipated harvest using DEA-registered laboratories. Samples must be analyzed for total THC using gas or liquid chromatography. The measurement uncertainty of the test must be included, and results above 0.3% total THC render the crop non-compliant. Growers may remediate crops testing between 0.3% and 1.0% by removing flower material; those above 1.0% must destroy the entire crop and face potential negligence findings.

DEA Regulations on Hemp

DEA's August 2020 Interim Final Rule (85 Fed. Reg. 51639) implemented the 2018 Farm Bill's CSA amendments. The rule established that hemp meeting the statutory definition is not a controlled substance, but added critical caveats: synthetically derived THC isomers remain Schedule I, and cannabis extracts must be derived from hemp meeting the definition at the time of extraction. This means CBD extracted from a plant later found to exceed 0.3% delta-9 THC is a controlled substance, even if the CBD itself contains no THC.

FDA's Position on Hemp-Derived CBD

FDA has not established a legal pathway for CBD in food or dietary supplements. The agency's position, articulated in warning letters and public statements, holds that CBD is excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) because it was investigated as a drug (Epidiolex, approved June 2018) before being marketed as a supplement. FDA has issued more than 40 warning letters to CBD companies since 2019, primarily for unsubstantiated health claims rather than the mere presence of CBD.

In May 2023, FDA released a report concluding it lacks sufficient safety data to establish a regulatory framework for CBD in food. The agency called on Congress to create a new pathway, but no legislation has advanced as of August 2026.

Interstate Commerce Protections

Section 10114 of the 2018 Farm Bill (7 U.S.C. § 1639r) prohibits states from interfering with interstate transportation or shipment of hemp or hemp products produced in accordance with the statute. This preempts state laws that would ban compliant hemp, though states retain authority to regulate or prohibit hemp production within their borders. Idaho, which prohibited all hemp production until 2021, could not prevent compliant hemp from being transported through the state.

State-by-State Breakdown

State hemp programs vary significantly in licensing requirements, testing protocols, and permitted products, creating a patchwork regulatory landscape that complicates interstate commerce and compliance.

California

California operates a USDA-approved hemp program administered by the California Department of Food and Agriculture under the California Hemp Production Program. The state requires registration for cultivation, with fees ranging from $900 to $5,000 based on acreage. California adopted USDA's total THC testing standard and 30-day harvest window. The state prohibits smokable hemp flower sales under Assembly Bill 45 (2021), which banned "industrial hemp products, including cannabinoid products derived from industrial hemp, that are orally ingested" without regulatory approval. As of August 2026, California had issued 412 hemp cultivation registrations covering approximately 3,200 acres.

Colorado

Colorado's hemp program, managed by the Colorado Department of Agriculture, predates the 2018 Farm Bill and transitioned to USDA approval in 2020. The state licenses approximately 1,450 growers on 6,700 acres. Colorado uses total THC testing with a 1% action threshold for negligence. The state banned delta-8 THC sales in 2021 under House Bill 21-1317, which classified synthetically derived cannabinoids as controlled substances. Colorado permits hemp-derived CBD in food and beverages under state law, creating conflict with FDA's position.

Kentucky

Kentucky, the 2018 Farm Bill's birthplace, operates one of the nation's largest hemp programs. The Kentucky Department of Agriculture licensed 1,840 growers on 8,200 acres in 2025. The state uses USDA's total THC standard but has advocated federally for raising the threshold to 1%. Kentucky permits CBD in food and beverages under state law and has not banned delta-8 THC or THCA flower, creating a robust hemp-derived cannabinoid market. The state requires processor licensing with fees of $2,500 annually.

New York

New York's hemp program, administered by the Department of Agriculture and Markets, received USDA approval in 2021. The state licensed 340 growers on 1,800 acres in 2025. New York banned delta-8 THC sales in 2022 under emergency regulations, later codified in the state's adult-use cannabis law. The state permits hemp-derived CBD in food under state law and requires cannabinoid hemp processors to obtain licenses through the Office of Cannabis Management, creating dual regulatory oversight.

Oregon

Oregon operates a USDA-approved program through the Oregon Department of Agriculture, with 980 licensed growers on 5,100 acres. The state pioneered hemp regulation in the 2014 Farm Bill era and maintains one of the most developed processing sectors. Oregon uses total THC testing and has proposed raising the state threshold to 1% total THC, pending federal approval. The state banned delta-8 THC in 2021 and regulates THCA flower as marijuana under Oregon Liquor and Cannabis Commission authority.

Vermont

Vermont's hemp program, managed by the Agency of Agriculture, Food and Markets, received USDA approval in 2020. The state licensed 285 growers on 920 acres in 2025. Vermont uses total THC testing with USDA's 30-day harvest window. The state permits hemp-derived CBD in food and has not banned delta-8 THC, but proposed emergency rules in August 2026 would classify THCA flower as marijuana. Vermont's small-scale craft hemp sector faces particular vulnerability to federal definition changes, as many growers operate on margins too thin to absorb crop losses from stricter testing.

Texas

Texas operates a USDA-approved program through the Texas Department of Agriculture, with 1,120 licensed growers on 4,300 acres. The state uses total THC testing and maintains a 0.3% limit. Texas initially banned delta-8 THC in 2021, but a state district court enjoined enforcement in 2022, leaving the market in legal limbo. The state permits THCA flower sales under current law, though the Department of State Health Services has proposed rules to classify it as marijuana. Texas prohibits smokable hemp flower under Health and Safety Code § 443.204.

Market and Business Implications

Changes to the federal hemp definition would trigger immediate financial consequences across cultivation, processing, retail, and ancillary service sectors, with potential losses exceeding $10 billion in the first year according to economic impact analyses.

Cultivation Economics

Hemp farmers operate on thin margins, with average revenue of $12,400 per acre and production costs of $9,800 per acre according to USDA's 2025 Hemp Benchmarks report. A shift from delta-9 THC to total THC measurement—already implemented in USDA rules but potentially made stricter—would increase crop failure rates. Cornell University's 2024 hemp variety trials found that 18% of compliant cultivars exceeded 0.3% total THC under field conditions, compared to 3% exceeding delta-9 THC limits. Raising the failure rate from 3% to 18% would cost growers an estimated $148 million annually in destroyed crops.

Genetics companies face research and development losses. Breeding programs invest 5-7 years developing stable cultivars; a definition change could obsolete entire seed catalogs. Oregon CBD Seeds, one of the nation's largest hemp genetics companies, reported in July 2026 that a total THC threshold below 0.5% would render 60% of its catalog non-compliant, representing $4.2 million in sunk R&D costs.

Processing and Manufacturing

CBD extraction and processing facilities have invested more than $3.8 billion in infrastructure since 2018, according to Hemp Benchmarks. These facilities rely on consistent feedstock supply; definition changes that reduce available biomass would create capacity underutilization. A processor operating at 40% capacity due to feedstock shortages cannot cover fixed costs, forcing consolidation or closure. The industry has already seen significant contraction, with licensed processors declining from 4,100 in 2020 to 3,200 in 2025.

Manufacturers of finished goods face inventory risk. A definition change that reclassifies existing products as non-compliant would require recalls and disposal. The average CBD brand carries 90-120 days of inventory; a sudden reclassification could strand $1.8 billion in finished goods based on industry inventory-to-sales ratios.

Retail and Distribution

Hemp-derived CBD products are sold through an estimated 35,000 retail locations including health food stores, pharmacies, convenience stores, and dedicated CBD shops. These retailers rely on the 2018 Farm Bill's safe harbor; a definition change that creates federal-state conflicts would force difficult decisions. Retailers in states where CBD remains legal under state law but becomes federally non-compliant face potential DEA enforcement, asset forfeiture, and loss of business licenses.

Payment processing represents a critical vulnerability. Visa and Mastercard permit hemp CBD transactions based on current federal legality. A definition change could trigger network rule violations, forcing payment processors to terminate merchant accounts. The CBD industry processed an estimated $4.2 billion in card transactions in 2025; loss of card acceptance would devastate retail sales.

Investment and Capital Markets

Hemp companies have raised more than $2.1 billion in venture capital and private equity since 2018, according to Viridian Capital Advisors. Definition uncertainty has already chilled investment; total hemp sector funding declined 68% from 2021 to 2025. A restrictive definition change would likely trigger down rounds, asset write-offs, and portfolio company failures. Public companies including Charlotte's Web Holdings and CV Sciences have seen stock prices decline 40-60% since 2023 amid regulatory uncertainty.

What Experts Say

Scientists, legal scholars, and industry analysts have offered divergent perspectives on whether the 0.3% delta-9 THC threshold serves its intended purpose or requires revision based on pharmacology, enforcement practicality, and market realities.

Dr. Daniela Vergara, a cannabis geneticist at the University of Colorado Boulder, has argued that the 0.3% threshold lacks scientific basis for distinguishing intoxicating from non-intoxicating cannabis. In a 2024 paper published in the Journal of Cannabis Research, Vergara and colleagues wrote that THC content varies based on growing conditions, harvest timing, and post-harvest handling, making a single threshold "arbitrary and unworkable." The researchers proposed a 1% total THC threshold to account for natural variation and testing uncertainty.

Jonathan Miller, general counsel of the U.S. Hemp Roundtable, has stated that the current definition creates "perverse incentives" for manufacturers to exploit loopholes rather than develop compliant products. According to Miller, the delta-8 THC and THCA flower markets demonstrate that "bright-line rules based solely on delta-9 THC measurement cannot prevent intoxicating products from entering commerce under the hemp umbrella." He has advocated for a regulatory framework that considers intended use and effect rather than chemical composition alone.

Former DEA attorney Shane Pennington, now a partner at Vicente Sederberg LLP, has argued that the 2018 Farm Bill's language is clear and unambiguous: hemp is defined by delta-9 THC content, period. In a 2025 law review article, Pennington wrote that "administrative agencies lack authority to rewrite statutory definitions through rulemaking," and that USDA's total THC testing protocol exceeds the agency's statutory mandate. He has represented hemp companies challenging agency overreach in federal court.

Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, has emphasized that THC content alone does not determine intoxication potential. In testimony before the House Energy and Commerce Committee in March 2026, Grant explained that "the entourage effect of multiple cannabinoids and terpenes, route of administration, and individual metabolism all affect psychoactive response." Grant suggested that functional impairment testing, similar to alcohol field sobriety tests, may be more appropriate than arbitrary chemical thresholds for regulatory purposes.

State regulators have expressed frustration with federal uncertainty. Vermont Agriculture Secretary Anson Tebbetts told VTDigger in August 2026 that "we built an entire regulatory program around the 2018 definition, licensed hundreds of businesses, and now face the possibility that federal agencies will pull the rug out through administrative rulemaking." Tebbetts called for congressional action to provide clarity and stability.

What's Next: Regulatory Calendar and Scenarios

Multiple federal decision points in late 2026 and 2027 will determine whether the hemp definition remains stable or undergoes significant revision, with state legislative sessions and court decisions adding additional variables.

USDA Rulemaking Timeline

USDA has indicated it will publish a Notice of Proposed Rulemaking in the fourth quarter of 2026 to address stakeholder concerns about the hemp production program. The agency's regulatory agenda, published in June 2026, lists "Hemp Production Program Revisions" with an anticipated NPRM in November 2026. Potential changes include adjustments to the total THC threshold, harvest testing windows, and remediation procedures. The NPRM will trigger a 60-day comment period, with a final rule unlikely before mid-2027.

DEA Scheduling Review

DEA's ongoing review of marijuana scheduling under the Biden administration's directive could indirectly affect hemp. If marijuana is rescheduled to Schedule III, as recommended by the Department of Health and Human Services in August 2023, the legal distinction between hemp and marijuana becomes less critical for criminal enforcement purposes. However, rescheduling would not change the statutory hemp definition or resolve conflicts over delta-8 THC and THCA. DEA's final scheduling decision, delayed multiple times, is now expected in early 2027 following completion of administrative law judge hearings.

Congressional Action Prospects

The 2024 Farm Bill reauthorization, delayed into 2026, may address hemp definition issues. Senator Rand Paul of Kentucky introduced the Hemp Economic Mobilization Plan (HEMP) Act in March 2026, which would raise the THC threshold to 1% total THC and create an FDA regulatory pathway for CBD in food and supplements. The bill has 12 Senate cosponsors but faces opposition from law enforcement groups and anti-legalization advocates. House Agriculture Committee Chairman GT Thompson has indicated openness to hemp provisions but stated that "intoxicating hemp products that circumvent state marijuana laws" require federal response.

Litigation Developments

The Ninth Circuit's decision in Hemp Industries Association v. DEA, addressing whether synthetically derived delta-8 THC is exempt from CSA scheduling, is expected in late 2026 or early 2027. A ruling favoring the industry could open the door to broader hemp-derived cannabinoid markets; a ruling for DEA would provide the agency with enforcement authority to shut down delta-8 and similar products. The case has attracted am